Fox Chase Cancer Center Appoints International Expert as Chief Scientific Officer
PHILADELPHIA (July 2008) — Jeff Boyd, Ph.D., of the Curtis and Elizabeth Anderson Cancer Institute and Memorial University Medical Center in Savannah, Georgia, has been appointed Chief Scientific Officer at Fox Chase Cancer Center. As Chief Scientific Officer, Boyd will be tasked with coordinating and charting the future course of research at Fox Chase.
Boyd is an international expert in translational research and has particular expertise in the genetics of breast, ovarian and endometrial cancer. He has helped define the role of tumor suppressors and oncogenes in these malignancies, most notably the p53, BRCA1 and BRCA2 tumor suppressor genes and their role in the development of breast and ovarian cancer.
"Jeff is bright, a powerful communicator, and possesses impeccable integrity in the setting of strong accomplishments in science. Indeed, during his 30 years in science, he has spent an extraordinary amount of time not only immersed in cancer biology and genetics, but also working closely with surgeons, medical oncologists, and radiation oncologists. He has a keen understanding of special skills and challenges relevant to each of these disciplines in executing a robust translational research mission," said Michael V. Seiden, M.D., Ph.D., president and CEO of Fox Chase.
According to Boyd, the continued success of both basic and clinical science at Fox Chase has laid the groundwork for a series of advances that will ultimately prevent most cancers from happening or transform currently incurable cancers into chronic, treatable conditions. Fox Chase, he believes, is uniquely suited to lead cancer medicine into this new era.
"As I've gotten to know the Fox Chase community, I've noticed an unusually high degree of collegiality and cooperation among its scientists and physicians, most obviously expressed through the Keystone Programs for Collaborative Discovery. These traits are essential components of high-quality translational research programs," said Boyd. "I'm looking forward to working with the researchers of Fox Chase to continue creating programs that capitalize on our current scientific strengths in order to anticipate - and meet - the future needs of medicine."
Boyd's most recent position was director of the Curtis and Elizabeth Anderson Cancer Institute and vice president of oncology and research at the Memorial University Medical Center in Savannah, Georgia. He also served as the professor of medicine, surgery, obstetric and gynecology at the Mercer University School of Medicine. At Mercer University, he served as the assistant dean of research. He also holds the title of Distinguished Cancer Scholar from the State of Georgia.
Prior to his roles in Savannah, Boyd served a variety of leadership roles at the Memorial Sloan Kettering Cancer Center in New York. At MSKCC, he was director of the gynecology and breast research laboratory in the department of surgery as well as the director of diagnostic molecular genetics laboratory within the department of medicine. Before serving at MSKCC, he had faculty positions at the University of Pennsylvania, the University of North Carolina and the National Institutes of Health (NIH).
Media inquiries only, please contact Gregory Lester at 215-728-2753.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.